International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Abstract Background Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting)...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Jan Beyer-Westendorf, A. John Camm, Keith A. A. Fox, Jean-Yves Le Heuzey, Sylvia Haas, Alexander G. G. Turpie, Saverio Virdone, Ajay K. Kakkar, for the RIVER Registry Investigators
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2019-04-01
Серии:Thrombosis Journal
Предметы:
Anticoagulant
Antithrombotic
Atrial fibrillation
Outcomes
Registry
Rivaroxaban
Online-ссылка:http://link.springer.com/article/10.1186/s12959-019-0195-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы